Jan C. Fagerberg
Keine laufenden Positionen mehr
Profil
Jan C.
Fagerberg served as the Chief Medical Officer & SVP at Amgen Rockville, Inc. from 2009 to 2011.
Prior to that, he was the Medical Director at Topotarget A in 2009.
He also served as an Independent Director at Response Genetics, Inc. in 2010 and 2011.
Fagerberg earned a doctorate degree from Karolinska Institutet in 1988.
Ehemalige bekannte Positionen von Jan C. Fagerberg
| Unternehmen | Position | Ende |
|---|---|---|
| RESPONSE GENETICS, INC | Direktor/Vorstandsmitglied | 12.10.2011 |
| TOPOTARGET A/S | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2009 |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Jan C. Fagerberg
| Karolinska Institutet | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RESPONSE GENETICS, INC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
